Skip to main content
SpringerLink
Log in

The French medicines regulator Afssaps has warned prescribers about the potential non-Hodgkin's lymphoma risk with off-label infliximab

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. French agency warns about off-label Remicade use in under 18s. Scrip: 21, No. 3169, 28 Jun 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The French medicines regulator Afssaps has warned prescribers about the potential non-Hodgkin's lymphoma risk with off-label infliximab. React. Wkly. 1109, 2 (2006). https://doi.org/10.2165/00128415-200611090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611090-00003

Keywords

Search

Navigation